HEXO Corp. General and Administrative Expenses 2011-2026 | HEXO

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses HEXO Corp.

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	58.2 M	78.6 M	74 M	14.4 M	4.27 M	-	216 K	29.3 K	-	-	-

All numbers in CAD currency

Indicator range from annual reports

Maximum	Minimum	Average
78.6 M	29.3 K	32.8 M

General and Administrative Expenses of other stocks in the Drug manufacturers industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Aerie Pharmaceuticals AERI	138 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	170 M	$ 1.11	4.25 %	$ 119 M	Canada
AcelRx Pharmaceuticals ACRX	8.53 M	-	7.5 %	$ 6.35 M	USA
Catalent CTLT	935 M	-	-	$ 11.5 B	USA
Adamis Pharmaceuticals Corporation ADMP	13.2 M	-	0.86 %	$ 117 M	USA
DURECT Corporation DRRX	14.4 M	-	-	$ 50.1 M	USA
Endo International plc ENDP	568 M	-	-	$ 28.9 M	Irlanda
Agile Therapeutics AGRX	10.5 M	-	10.11 %	$ 58.2 M	USA
Evoke Pharma EVOK	12.2 M	-	-	$ 36.6 M	USA
Evolus EOLS	221 M	$ 5.61	35.71 %	$ 362 M	USA
Alimera Sciences ALIM	18.5 M	-	-	$ 142 M	USA
Cronos Group CRON	95.9 M	$ 2.66	2.31 %	$ 1.39 B	Canada
Avadel Pharmaceuticals plc AVDL	181 M	-	-	$ 2.06 B	France
Harrow Health HROW	153 M	$ 39.84	3.2 %	$ 1.46 B	USA
Jupiter Wellness JUPW	39.6 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	1.78 M	$ 0.58	4.82 %	$ 10.1 M	China
Cumberland Pharmaceuticals CPIX	11.1 M	$ 3.93	-14.3 %	$ 55.3 M	USA
Calliditas Therapeutics AB (publ) CALT	390 M	-	-0.1 %	$ 2.03 B	Schweden
Neoleukin Therapeutics NLTX	11.2 M	-	-	$ 193 M	Canada
Aurora Cannabis ACB	119 M	$ 3.67	5.46 %	$ 86.3 M	Canada
Athenex ATNX	44.9 M	-	-23.39 %	$ 1.76 M	USA
Organogenesis Holdings ORGO	295 M	$ 2.96	2.96 %	$ 390 M	USA
Emergent BioSolutions EBS	368 M	$ 8.93	0.17 %	$ 457 M	USA
ProPhase Labs PRPH	34.4 M	-	-	$ 5.07 M	USA
Assertio Holdings ASRT	78.6 M	$ 12.19	2.44 %	$ 866 M	USA
Radius Health RDUS	131 M	-	-	$ 1.42 B	USA
Bausch Health Companies BHC	2.92 B	$ 5.65	-1.4 %	$ 2.06 B	Canada
Lannett Company LCI	81 M	-	1.15 %	$ 7.11 M	USA
Eagle Pharmaceuticals EGRX	107 M	-	-39.89 %	$ 27.7 M	USA
OrganiGram Holdings OGI	12.8 M	$ 1.41	3.2 %	$ 402 M	Canada
Perrigo Company plc PRGO	436 M	$ 11.63	2.15 %	$ 1.61 B	USA
Rockwell Medical RMTI	12.1 M	$ 0.9	0.44 %	$ 21 M	USA
Sundial Growers SNDL	38.4 M	$ 1.56	1.63 %	$ 3.37 M	Canada
TherapeuticsMD TXMD	8.9 M	$ 2.25	1.35 %	$ 23.5 M	USA
Pacira BioSciences PCRX	294 M	$ 22.89	3.57 %	$ 1.06 B	USA
Veru VERU	31.2 M	$ 2.6	3.17 %	$ 351 M	USA
PetIQ PETQ	196 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	79.8 M	-	-	$ 1.08 B	USA
Viatris VTRS	4.07 B	$ 14.81	-0.57 %	$ 17.8 B	USA
PLx Pharma PLXP	40 M	-	-27.8 %	$ 2.56 M	USA
Recro Pharma REPH	21 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	48.9 M	$ 4.76	2.03 %	$ 143 M	USA
SCYNEXIS SCYX	20.9 M	$ 0.76	0.96 %	$ 36.4 M	USA
Solid Biosciences SLDB	33.3 M	$ 6.26	5.03 %	$ 256 M	USA
Sonoma Pharmaceuticals SNOA	7.36 M	$ 2.74	-0.36 %	$ 3.4 M	USA
Tricida TCDA	37.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	165 M	$ 7.45	1.22 %	$ 4.6 B	Canada
Zynerba Pharmaceuticals ZYNE	14.2 M	-	-	$ 55.5 M	USA